SONIRE Therapeutics Announces Publication of Joint Research Results with Tokyo University of Pharmacy and Life Sciences

SONIRE Therapeutics Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Tohru Satoh; hereinafter “the Company”) is pleased to announce that the results of its joint research with Tokyo University of Pharmacy and Life Sciences have been published in a peer-reviewed academic journal. This research was conducted in collaboration with Associate Professor Rui Tada of the Laboratory for Immunopharmacology of Microbial Products and Professor Yoichi Negishi of the Laboratory of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.

Publication Details
Title: Cavitation bubble-assisted high-intensity focused ultrasound induces abscopal immune responses
Journal: International Immunopharmacology
Article URL: https://www.sciencedirect.com/science/article/pii/S1567576925015565

In this study, Trigger HIFU for a small-animal model based on the same principle as SONIRE’s HIFU therapy system (development code: Suizenji) was used to evaluate the immune-stimulating effects of HIFU on tumors. Trigger HIFU was applied only to the right-side tumor in mice bearing tumors on both flanks, a significant suppression of tumor growth was also observed in the untreated left-side tumor. Detailed mechanistic analyses revealed an increase in tumor-infiltrating cytotoxic T cells, demonstrating that Trigger HIFU activates CD8+ T cell-dependent anti-tumor immunity and may exert systemic effects even on distant metastatic lesions.

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: “Sonics brings a hopeful new future to as many cancer patients and their families as possible.”

Download PDF file

Announcement of Establishment of U.S. Subsidiary

SONIRE Therapeutics Co., Ltd. (Head Office: Chuo-ku, Tokyo; President & CEO: Tohru Satoh; hereinafter “the Company”) is pleased to announce the establishment of its U.S. subsidiary, SONIRE Therapeutics Inc., effective September 1, 2025.

The U.S. subsidiary is located within the Japan Innovation Campus (JIC) in Palo Alto, California. JIC is a support hub founded under the initiative of Japan’s Ministry of Economy, Trade and Industry and Mori Building Co., Ltd., designed to assist Japanese startups in expanding their businesses in the United States.

Overview of U.S. Subsidiary
Company Name : SONIRE Therapeutics Inc.
Address : 214 Homer Ave, Palo Alto, CA 94301 (inside Japan Innovation Campus)
Representative : Tohru Satoh

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: “Sonics brings a hopeful new future to as many cancer patients and their families as possible.”

Download PDF file

SONIRE Therapeutics CEO Tohru Satoh to speak at MEDICA 2024

SONIRE Therapeutics Inc. (Headquarters: Tokyo, Japan; President and CEO, Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that Mr. Tohru Satoh will be speaking at the Future of Therapy session of Pitch Event at MEDICA 2024, the world’s largest medical equipment trade fair, to be held in Düsseldorf, Germany from 11th to 14th November 2024. The title of the presentation will be “Cancer treatment using ultrasound technology”.

Date and time:
November 13th (Wed) 12:45 – 12:55 (CET) (20:45 – 20:55 (JST))
Place: MEDICA INNOVATION FORUM (MIF) Hall 13 Booth E63

For information on the presentations, please refer to the following website.
https://www.medica-tradefair.com/en/Program/Programoverview?ems_event=mif-cancer-treatment-using-ultrasound-technology-432066

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics brings new future full of hope to as many cancer patients and their families as possible.”.

Download PDF file

SONIRE’s HIFU therapy system has been designated as a Breakthrough Device by FDA

SONIRE Therapeutics Inc. (Headquarters: Tokyo, Japan; President and CEO, Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that the next-generation HIFU (High-Intensity Focused Ultrasound) therapy system (development code: Suizenji) developed by SONIRE has been designated as a breakthrough device by the U.S. Food and Drug Administration (hereinafter referred to as “FDA”) for the treatment of pancreatic cancer.

The Breakthrough Device Program supports the development of medical devices that provide more effective treatment or diagnostic of life-threatening or irreversible human diseases.

Through this program, SONIRE will receive an opportunity to interact with FDA experts through different program options to efficiently address topics as SONIRE arises during premarket review phase. Therefore, it is expected that this program accelerates for patients to access the new treatment provided by Suizenji as soon as possible.

For more information about the Breakthrough Device Program, please refer to the FDA website.
https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics brings new future full of hope to many cancer patients and their families as possible.”.

Download PDF file

HIFU treatment for pancreatic cancer will be broadcast on NHK WOLRD

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that NHK WOLRD’s “Medical Frontiers” will focus on HIFU therapy for pancreatic cancer, and the next-generation HIFU (High-Intensity Focused Ultrasound) therapy device, which has been developed by SONIRE, will be introduced in the program.

The program outline is as follows.
Title : Destroying Pancreatic Cancer With Ultrasound
Program Title : NHK World “Medical Frontiers”
Broadcast date and time :
January 8 (Mon) 23:30（JST）
January 9 (Tue) 05:30（JST）  [Rebroadcast]
January 9 (Tue) 12:30（JST）  [Rebroadcast]
January 9 (Tue) 18:30（JST）  [Rebroadcast]
January 27 (Sat) 04:30（JST） [NHK BS1]
Live streaming broadcast :
You can watch the live streaming from the official website.
https://www.nhk.or.jp/nhkworld/en/live/

On-demand Broadcasting :
After the rebroadcast ends, the program can be viewed for one year via on-demand broadcasting.
https://www.nhk.or.jp/nhkworld/en/tv/medicalfrontiers/

For details, please refer to the following URL.
https://www.nhk.or.jp/nhkworld/en/tv/medicalfrontiers/20240108/2050151/

SONIRE will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer Patients and Families.”.

Download PDF file

Notice of Adoption being seleced for “Deep Tech Startup Support Program” by New Energy and Industrial Technology Development Organization (NEDO)

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO, Co-
Founder: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that our project
“Research and Development of Next-Generation Focused Ultrasound Therapy System for
Intractable Cancer” has been selected for the PCA (Product Commercialization Alliance)
phase of the Deep Tech Startup Support Program implemented by New Energy and Industrial
Technology Development Organization (NEDO).

The adoption of this program will further accelerate the development of our “next-generation
HIFU (High-Intensity Focused Ultrasound) therapy device”.

We will continue to promote our business in order to realize the wish we put in our company
name at the time of our foundation: ” Sonics（Ultrasound） Brings New Future to Cancer
Patients and their Families.”.

Download PDF file